Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

This single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or serous uterine carcinoma treated with primary surgery were included. These were classified into three groups: No treatment or brachytherapy only (G1), radiotherapy +/− brachytherapy (G2), chemotherapy +/− radiotherapy +/− brachytherapy (G3). In total, we included 52 patients: 18 patients in G1, 16 in G2, and 18 in G3. Patients in the G3 group presented with poorer prognostic factors: 83.3% had serous histology, 27.8% LVSI, and 27.8% were FIGO stage IB. Patients treated with adjuvant radiotherapy showed an improved 5-year overall survival (OS) (p = 0.02) and a trend towards an enhanced 5-year progression-free survival (PFS) (p = 0.056). In contrast, OS (p = 0.97) and PFS (p = 0.84) in the chemotherapy group with poorer prognostic factors, were similar with increased toxicity (83.3%). Radiotherapy is associated with improved 5-year OS and tends to improve 5-year PFS in women with stage I clear cell and serous uterine carcinoma. Additional chemotherapy should be cautiously considered in serous carcinoma cases presenting poor histological prognostic factors.

[1]  I. Shih,et al.  Uterine serous carcinoma: key advances and novel treatment approaches , 2021, International Journal of Gynecological Cancer.

[2]  A. Mariani,et al.  Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer , 2021, International Journal of Gynecological Cancer.

[3]  Cyrus Chargari,et al.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.

[4]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[5]  V. Tombolini,et al.  The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review , 2020, Journal of contemporary brachytherapy.

[6]  B. Fellman,et al.  Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience , 2019, Gynecologic Oncology.

[7]  Jae-Weon Kim,et al.  Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Kidd,et al.  National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma. , 2019, Gynecologic oncology.

[9]  D. DeLair,et al.  Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma. , 2019, Brachytherapy.

[10]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.

[11]  Kathleen R. Cho,et al.  Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  Jason D. Wright,et al.  Utility of radiation therapy for early-stage uterine papillary serous carcinoma. , 2017, Gynecologic oncology.

[13]  H. Putter,et al.  Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[14]  E. Darai,et al.  Endometrial cancer , 2016, The Lancet.

[15]  M. Bernardini,et al.  Uterine Clear Cell Carcinoma: Does Adjuvant Chemotherapy Improve Outcomes? , 2016, International Journal of Gynecologic Cancer.

[16]  T. Kalir,et al.  Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis , 2016, International Journal of Gynecologic Cancer.

[17]  D. D'Souza,et al.  Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy? , 2015, International Journal of Gynecologic Cancer.

[18]  Rochelle L. Garcia,et al.  An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers , 2015, Journal of gynecologic oncology.

[19]  R. Yechieli,et al.  Adjuvant Radiation Therapy for Patients With Type II Endometrial Carcinoma: Impact on Tumor Recurrence and Survival , 2013, International Journal of Gynecologic Cancer.

[20]  M. Birrer,et al.  Uterine papillary serous cancer: a review of the literature. , 2012, Gynecologic oncology.

[21]  S. Lewin.  Revised FIGO staging system for endometrial cancer. , 2011, Clinical obstetrics and gynecology.

[22]  P. Gehrig,et al.  Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[23]  L. Havrilesky,et al.  Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma , 2009, Cancer.

[24]  A. Olawaiye,et al.  Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[25]  D. Mutch,et al.  Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. , 2008, Gynecologic oncology.

[26]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[27]  P. Boyle,et al.  Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. , 2004, Gynecologic oncology.

[28]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[29]  P. Clement,et al.  Endometrioid Carcinoma of the Uterine Corpus: A Review of Its Pathology With Emphasis on Recent Advances and Problematic Aspects , 2002, Advances in anatomic pathology.

[30]  T. Herzog,et al.  Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. , 2003, Gynecologic oncology.